Predictive Oncology Inc.
POAI
$0.95
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -97.55% | -81.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.55% | -81.97% | |||
| Cost of Revenue | -59.65% | -84.48% | |||
| Gross Profit | -123.77% | -79.69% | |||
| SG&A Expenses | 12.42% | -3.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.06% | -12.35% | |||
| Operating Income | -16.31% | -7.69% | |||
| Income Before Tax | 13.41% | -8.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.41% | -8.78% | |||
| Earnings from Discontinued Operations | 41.84% | -129.26% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.24% | -12.60% | |||
| EBIT | -16.31% | -7.69% | |||
| EBITDA | -16.54% | -8.20% | |||
| EPS Basic | 33.46% | -5.11% | |||
| Normalized Basic EPS | 32.00% | -1.58% | |||
| EPS Diluted | 32.72% | -5.23% | |||
| Normalized Diluted EPS | 32.00% | -1.58% | |||
| Average Basic Shares Outstanding | 27.36% | 7.14% | |||
| Average Diluted Shares Outstanding | 27.36% | 7.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||